Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal randomized, double-blind, multicenter, placebo-controlled Phase 3 trial of the oral solution containing tranexamic acid to prevent possible oral haemorrhaging in patients treated with anticoagulants (blood thinners) and undergoing extraction of one or more teeth

Next Previous
Trial Profile

A pivotal randomized, double-blind, multicenter, placebo-controlled Phase 3 trial of the oral solution containing tranexamic acid to prevent possible oral haemorrhaging in patients treated with anticoagulants (blood thinners) and undergoing extraction of one or more teeth

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tranexamic acid (Primary)
  • Indications Haemorrhage
  • Focus Registrational; Therapeutic Use
  • Sponsors Hyloris Pharmaceuticals

Most Recent Events

  • 14 Feb 2024 According to a Hyloris Pharmaceuticals media release, data from the Phase 1 allowed Hyloris to define the optimal administration regimen for its proprietary oral solution for this current Phase 3 trial.
  • 14 Feb 2024 According to a Hyloris Pharmaceuticals media release, recruitment is expected to be completed around the end of 2024 with final results available in the first half of 2025. An estimated 280 patients will be recruited at approximately 20 clinical sites across Europe and the United States.
  • 14 Feb 2024 Status changed from planning to recruiting, according to a Hyloris Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top